NCT01364441View on ClinicalTrials.gov

Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

August 31, 2011

Conditions

Healthy Adult Subjects

Interventions

DRUG

ONO-2952

3 mg to 800 mg at a single dose; 10 mg and 200 mg for food effect study

DRUG

Placebo

Placebo dosed in the same manner as ONO-2952

Trial Locations (1)

78744

Austin Clinical Site, Austin

Sponsors

Lead Sponsor

Ono Pharma USA Inc

All Listed Sponsors

lead

Ono Pharma USA Inc

INDUSTRY